Human CD16 Separation Beads

Our laboratory investigates different ways to improve immune responses against HIV, including enhancement of the capacity of effector cells, such as NK cells, to kill HIV-infected cell. We are currently investigating the capacity of an engineered antibody to trigger NK-cell mediated ADCC activity in in vitro assays against an HIV-infected cell line. In order to confirm whether the antibody protection mechanism is through the interaction with the FcRgamma IIIa (CD16), we use either human PBMC, or CD16 depleted PBMC as effector cells in our assays.